文献速递骨质疏松与代谢性骨病

质子泵抑制剂与骨折风险:挪威HUNT研究

Proton pump inhibitors and fracture risk. The HUNT study, Norway.
PubMed 文献 · Osteoporos Int · 2019-11-18

基于挪威HUNT3队列15,017名女性和13,241名男性(50-85岁),随访中位5.2年,采用时依Cox模型分析质子泵抑制剂(PPI)使用与首次前臂或髋部骨折的关联。年龄校正后女性HR 0.82(0.67-1.01),男性HR 1.05(0.72-1.52);进一步校正年龄、抗骨质疏松药物和FRAX后,女性HR降至0.80(0.65-0.98),男性HR 1.00(0.69-1.45)。结论认为PPI使用与骨折风险增加无关。

要点

  • 女性PPI使用者17.9%,男性15.5%。
  • 随访中位5.2年,女性首次髋部骨折266例、前臂骨折662例;男性髋部134例、前臂127例。
  • 校正年龄、抗骨质疏松药物和FRAX后,女性HR 0.80(0.65-0.98),男性HR 1.00(0.69-1.45)。

核心结论

  • PPI使用与骨折风险增加无关。

研究设计与样本

  • 基于挪威HUNT3研究、Nord-Trøndelag骨折登记和挪威处方数据库,纳入15,017名女性和13,241名男性(50-85岁)。
  • 随访从参与HUNT3(2006-2008)至首次前臂或髋部骨折、死亡或研究结束(2012年12月31日)。
  • 采用时依Cox比例风险模型,PPI暴露定义为处方至少相当于90个限定日剂量(DDD),暴露持续至药物供应结束后6个月。

主要发现

  • 女性PPI使用者17.9%,男性15.5%。
  • 女性前臂和髋部骨折合计率:PPI使用者49.2/1000人年 vs 非使用者64.1/1000人年;男性分别为18.6/1000人年 vs 19.8/1000人年。
  • 年龄校正后首次前臂或髋部骨折HR:女性0.82(0.67-1.01),男性1.05(0.72-1.52)。
  • 进一步校正年龄、抗骨质疏松药物和FRAX后,女性HR 0.80(0.65-0.98),男性HR 1.00(0.69-1.45)。

关键数值与推荐

  • PPI暴露定义:处方至少相当于90个限定日剂量(DDD)。
  • 暴露持续至药物供应结束后6个月。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Proton pump inhibitors (PPIs) have been linked to increased risk of fracture; the data have, however, been diverging. We did not find any increased risk of fractures among users of PPIs in a Norwegian population of 15,017 women and 13,241 men aged 50-85 years with detailed information about lifestyle and comorbidity. INTRODUCTION: Proton pump inhibitors (PPIs) are widely prescribed and have been linked to increased risk of fracture. METHODS: We used data from the Nord-Trøndelag Health Study (HUNT3), The Fracture registry in Nord-Trøndelag, and the Norwegian Prescription Database, including 15,017 women and 13,241 men aged 50-85 years. The study population was followed from the date of participating in HUNT3 (2006-2008) until the date of first fracture (forearm or hip), death, or end of study (31 December 2012). The Cox proportional hazards model with time-dependent exposure to PPIs was applied, and each individual was considered as unexposed until the first prescriptions was filled. To be included, the prescription of PPIs should minimum be equivalent to 90 defined daily doses (DDD) in the period. Individuals were defined as exposed until 6 months after end of drug supply. RESULTS: The proportion of women and men using PPIs was 17.9% and 15.5%, respectively. During a median of 5.2 years follow-up, 266 women and 134 men had a first hip fracture and 662 women and 127 men, a first forearm fracture. The combined rate/1000 patient-years for forearm and hip fractures in women was 49.2 for users of PPIs compared with 64.1 among non-users; for men 18.6 and 19.8, respectively. The hazard ratios with 95% confidence interval for the first forearm or hip fracture among users of PPIs in the age-adjusted analysis were 0.82 (0.67-1.01) for women and 1.05 (0.72-1.52) for men. Adjusting for age, use of anti-osteoporotic drugs, and FRAX, the HR declined to 0.80 (0.65-0.98) in women and 1.00 (0.69-1.45) in men. CONCLUSIONS: Use of PPIs was not associated with an increased risk of fractures.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Hoff M, Skovlund E, Skurtveit S, et al. Proton pump inhibitors and fracture risk. The HUNT study, Norway. Osteoporos Int. 2019. PMID: 31741023. doi:10.1007/s00198-019-05206-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。